MeMed awarded US BARDA contract to demonstrate clinical utility of the FDA-cleared MeMed BV® test for distinguishing bacterial from viral infections
Contract awarded under the BARDA DRIVe (Division of Research, Innovation, and Ventures) initiative to harness a patient’s systemic response to inform on health threats and clinical impact TIRAT CARMEL, Israel; BOSTON, MA – 24 October, 2023 – MeMed, a leader in host response technologies, is pleased to announce that it